TITLE

Alpha-1 -antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics

AUTHOR(S)
Soy, D.; de Ia Roza, C.; Lara, B.; Esquinas, C.; Torres, A.; Miravitlles, M.
PUB. DATE
December 2006
SOURCE
Thorax;Dec2006, Vol. 61 Issue 12, p1059
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Exogenous doses of 60 mg/kg α1-antitrypsin (AAT) every 7 days are recommended in patients with severe AAT deficiency. However, long term administration of weekly doses is not well accepted by patients. Using pharmacokinetic simulations, we evaluated whether steady state minimum concentrations of total AAT can be maintained above the threshold of 0.5 g/l with longer intervals between doses. Methods: Several sets of exogenous AAT versus time simulations were studied using a non-linear mixed effect approach with dosage regimens every 7, 14, 21, and 28 days. For each regimen the mean exogenous AAT trough concentrations and 5/95th percentiles were determined. The results obtained were applied to estimate the individual optimal dose at 7, 14, and 21 days in six patients using Bayesian analysis. Results: The simulations showed that a dose of 50 mg/kg AAT every 7 days was sufficient to obtain nadir concentrations. Doses of 120 and 100 mg/kg every 14 days were also adequate, but 180 mg/kg given every 21 days required total AAT monitoring to avoid underdosage. Longer intervals were inappropriate. Dosage individualisation confirmed that AAT infusions given every 14 days maintained the nadir level of 0.5 g/I without a significant dose increase compared with current practice. When the time span between doses was fixed at 21 days, a mean relative AAT dose enhancement of 91% and 13%, respectively, was required to achieve sustained total AAT concentrations above the target level for 100% and 85% of the interval between doses. Conclusions: It is feasible to extend the interval between doses of AAT to 14 or 21 days to achieve adequate trough total AAT concentrations. This study might be used as a starting point for clinical evaluation of the regimens described.
ACCESSION #
23496424

 

Related Articles

  • Alpha-1 -antitrypsin augmentation treatment: does one size fit all? Stolk, J. // Thorax;Dec2006, Vol. 61 Issue 12, p1034 

    The article focuses on the pharmacokinetic assessment (PA) patients requiring alpha 1-antitrypsin (AAT) augmentation therapy. This therapy involves the intravenous administration of purified AAT to raise serum levels above the protective threshold. The risk of emphysema increases as the serum...

  • Alpha1-Antitrypsin Deficiency – A Model for Conformational Diseases. Carrell, Robin W.; Lomas, David A. // New England Journal of Medicine;1/3/2002, Vol. 346 Issue 1, p45 

    The article focuses on the diseases caused by the deficiency of alpha-1-antitrypsin. The genetic deficiency of alpha-1-antitrypsin offers a model for the diseases which is related with abnormalities of various serpins, collectively known as the serpinopathies. The most noticeable feature is the...

  • © DISTRIBUTION OF THE SIX χ1-ANTITRYPSIN (PI) SUBTYPES FROM A SAMPLE OF BLOOD DONORS. Mulley, John C. // Australian Journal of Experimental Biology & Medical Science;Aug1980, Vol. 58 Issue 4, p409 

    Investigates the distribution of alpha 1-antitrypsin subtypes from blood donors in Adelaide, South Australia. Classification of phenotypes; Proportion of heterozygotes; Genetic variation in alpha 1-antitrypsin.

  • α1-ANTITRYPSIN AND α1-ANTITRYPSIN PHENOTYPING  // Davis's Comprehensive Handbook of Laboratory & Diagnostic Tests ;Jan2006, p164 

    αSB1sb-AT is the main glycoprotein produced by the liver. Its inhibitory function is directed against proteolytic enzymes, such as trypsin, elastin, and plasmin, released by alveolar macrophages and bacteria. In the absence of αSB1sb-AT, functional tissue is destroyed by proteolytic...

  • Endotoxin receptor CD14 in PiZ α-1-antitrypsin deficiency individuals. Sandström, Caroline S.; Novoradovskaya, Natalia; Cilio, Corrado M.; Piitulainen, Eeva; Sveger, Tomas; Janciauskiene, Sabina // Respiratory Research;2008, Vol. 9, Special section p1 

    Background: CD14, a receptor for lipopolysaccharides (LPS), is found in both a membrane-bound form (mCD14) and a soluble form (sCD14). It is suggested that sCD14 is mainly released from blood monocytes by serine protease-mediated shedding. Because α1-antitrypsin (AAT), an inhibitor of serine...

  • Ben-Gurion University researcher talks possible diabetes cure. Zelaya, Ian // Washington Jewish Week;4/17/2014, Vol. 50 Issue 16, p8 

    The article discusses the statement of Eli Lewis, the director of Ben-Gurion University's Clinical Islet Laboratory, regarding the discovery of a possible treatment for Type 1 diabetes. Lewis and his team of researchers have recognized the important role played by inflammation in the disease and...

  • Fifty Years On: GWAS Confirms the Role of a Rare Variant in Lung Disease. Turner, Alice M. // PLoS Genetics;Aug2013, Vol. 9 Issue 8, p1 

    The article discusses research being done on alpha one antitrypsin deficiency (AATD). It references the study "Causal and Synthetic Association of Variants in the Serpina Gene Cluster With Alpha-Antitrypsin Serum Levels," by G. A. Thun et al. published in the 2013 issue of "PLoS Genetics." The...

  • Hepatoid carcinoma of the skin: spontaneous rat skin hepatoid carcinoma with eosinophilic globules and crystals immunoreactive to α-1-antitrypsin. Sutoh, Mihoko; Chiba, Mitsuru; Kasai, Kosuke; Miura, Tomisato; Nozaka, Hiroyuki; Washiya, Kiyotada; Okusawa, Etsuko; Oyama, Naoto; Tsutaya, Chikako; Tsushima, Megumi; Terayama, Yuriko; Funyu, Tomihisa; Sato, Tatsusuke // Medical Molecular Morphology;Jun2009, Vol. 42 Issue 2, p118 

    We present a case of hepatoid carcinoma of the abdominal skin in a male Wistar rat. Histopathologically, this carcinoma resembled human hepatocellular carcinoma with respect to trabecular-sinusoidal structures. Carcinoma tissues contain numerous eosinophilic globules and crystals, and in this...

  • Fibrillogenic C-terminal fragment of alpha-1-antitrypsin activates human monocytes via oxidative mechanisms. Bironaite, D.; Lindgren, S.; Janciauskiene, S. // Cell & Tissue Research;Jul2001, Vol. 305 Issue 1, p87 

    Production of alpha-1-antitrypsin by human monocytes is an important factor in controlling tissue damage by proteases in the microenvironment of inflammation. Increases of four- to eightfold in levels of native and fragmented forms of alpha-1-antitrypsin have been detected in inflammatory loci...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics